Pre-demographic dividend vs Thailand: Antiretroviral therapy coverage for PMTCT
Pre-demographic dividend
84.4%
in 2024
Thailand
97.0%
in 2024
Pre-demographic dividend rank
9th
Thailand rank
12th
Antiretroviral therapy coverage for PMTCT over time
- Pre-demographic dividend
- Thailand
How they compare
Thailand currently reports 97.0% against 84.4% in Pre-demographic dividend, a difference of 12.6%.
That makes Thailand's figure about 1.1 times Pre-demographic dividend's.
Across all 25 years both countries report, Thailand has been ahead every year.
Pre-demographic dividend ranks 9th and Thailand ranks 12th of 15 groups.
Thailand has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Pre-demographic dividend | Thailand | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 18.1% | 60.7% | 42.6% | Thailand |
| 2010s | 69.9% | 95.7% | 25.8% | Thailand |
| 2020s | 84.0% | 97.4% | 13.4% | Thailand |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher antiretroviral therapy coverage for pmtct, Pre-demographic dividend or Thailand?
- Thailand, at 97.0% against 84.4% in Pre-demographic dividend as of 2024.
- What is the difference in antiretroviral therapy coverage for pmtct between Pre-demographic dividend and Thailand?
- 12.6%, with Thailand ahead.
- How many years of comparable data are there for Pre-demographic dividend and Thailand?
- 25 years are reported by both, from 2000 to 2024.
- How do Pre-demographic dividend and Thailand rank globally for antiretroviral therapy coverage for pmtct?
- Pre-demographic dividend ranks 9th and Thailand ranks 12th of 15 groups.
- Where does this data come from?
- UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).